James Quincey Purchases Pfizer Stock on NYSE

James Quincey recently bought 1,595 shares of Pfizer Inc. (NYSE:PFE) on June 26, 2026. The purchase was made at an average price of $24.29 per share, bringing the total transaction value to $38,742.55. This move was not part of a pre-planned trading plan.

Insider Buying and Selling at Pfizer Inc.

On June 26, 2026, several insiders, including James Quincey, made purchases of Pfizer stock. Quincey acquired 1,595 shares at $24.29 each. Other insiders such as Joseph Echevarria and Shantanu Narayen also bought shares, with transactions at the same price, indicating a broader insider interest in the company.

Other Institutional Activity in Pfizer

Among institutional investors, BlackRock, Inc. increased its holdings by 5,195,022 shares, ending with 498,257,550 shares valued at approximately $13.99 billion, a 1.1% increase. Vanguard Capital Management LLC opened a new position with 369,430,012 shares, worth about $10.37 billion. State Street Corp added 1,144,701 shares to its portfolio, holding 301,589,865 shares valued at $8.47 billion, marking a 0.4% increase. Geode Capital Management, LLC grew its stake by 3,369,661 shares, reaching a total of 133,561,742 shares worth $3.74 billion, a 2.6% increase. Fisher Asset Management, LLC significantly boosted its position by 53,012,321 shares, now holding 104,964,427 shares valued at $2.95 billion, reflecting a 102% increase.

Pfizer Inc. Stock Down 15.4%

Shares of Pfizer Inc. traded near $24.37 on Wednesday. The company has a market cap of $138.4 billion, with a P/E ratio of 18.54 and a forward P/E of 8.59. Pfizer's stock has a 52-week low of $23.11 and a high of $28.75. Its 50-day moving average is $25.97, and the 200-day moving average is $25.87. The company maintains a current ratio of 1.25 and a quick ratio of 0.85, with a debt-to-equity ratio of 71.60.

Recent Earnings

Pfizer reported revenue of $63.32 billion, with a revenue growth of 5.4%. The company achieved a net margin of 11.83% and a return on equity of 8.31%. Earnings per share stood at $1.31. The next earnings report is scheduled for August 4, 2026.

Dividend

Pfizer offers an annual dividend rate of $1.72, yielding 7.08%. The dividend payout ratio is 131.3%.

Analysts Set New Price Targets

On April 29, 2026, Citigroup maintained a hold rating on Pfizer with a price target of $27. CICC initiated coverage on April 16, 2026, with a buy rating and a target of $33. UBS and Morgan Stanley also maintained hold ratings with price targets of $27 and $28, respectively. The consensus among 27 analysts is a buy rating, with an average price target of $29.15.

About Pfizer Inc.

Pfizer Inc. is a global biopharmaceutical company based in New York, NY. It focuses on discovering, developing, and selling healthcare products. The company's offerings include a broad range of medicines and vaccines in areas such as internal medicine, oncology, inflammation, immunology, and rare diseases. Led by CEO Dr. Albert Bourla, Pfizer employs approximately 75,000 people worldwide.

Bottom Line

James Quincey's recent purchase of Pfizer shares highlights ongoing interest in the company from insiders. Pfizer remains a significant player in the healthcare sector, with steady institutional interest and numerous analyst ratings. As always, insider transactions are just one piece of the puzzle for investors tracking the stock.